RDS raises €14 million to industrialize MultiSense®, aconnected patch for remote patient monitoring

Funds raised will help accelerate time to market in Europe for MultiSense

and scale industrial operations. Plans include starting a health economics study to support MultiSense’s reimbursement application, alongside preparing registration procedures

with US authorities, with an eye on US launch in 2028.

Strasbourg, France, September 29, 2025 – RDS, a French medtech company, today

announces a €14 million ($16.6M) Series A funding round. The SPI (Sociétés de Projets

Industriels) fund, managed on behalf of the French state by Bpifrance, led the round, with

Critical Path Ventures also taking a new stake. MACSF, Capital Grand Est and other

historical investors also contributed.

Investors are backing RDS’ MultiSense®, a CE-marked, class IIa remote monitoring

medical device, which provides healthcare professionals with a high-precision,

comprehensive solution for continuous monitoring of patients’ key physiological

parameters in hospital or at home. This innovative, clinically validated technology has

already been rolled out in 15 hospitals across France, Belgium and Germany. In the last

year, the device was added to the approved supplies list for RESAH and UniHA, leading

public purchasing bodies for hospitals in France.

RDS will use the funds to accelerate its development in France, Germany and the broader

European market. The company expects to create several hundred new jobs by 2035,

bolstering its sales team to meet the growing demand for the MultiSense solution. The

funds will also finance the industrialization of the solution that is manufactured in France,

with the aim of gradually ramping up production and refurbishing capacities.

Simultaneously, RDS will launch complementary clinical trials to support its applications

for reimbursement in France and across Europe. The company is also preparing to initiate

the FDA registration process, with a view to a US market launch in 2028.

“This investment gives us the means to ramp up our sales growth in Europe, consolidate

the clinical and health economic value of MultiSense, and get ready for market launch in

North America,” said Elie Lobel, CEO of RDS. “These funds mean we can roll out our solution

more widely to hospitals, expand its positive impact for patients and care teams, and

provide reliable, continuous, clinically validated remote monitoring to as many facilities as

possible. The funds raised are a testament to our investors’ enduring confidence in this

project and the team.”

With this financing, RDS will have raised a total of €28 million since its founding. The Series

A €14 million comes on top of the €14 million in capital and non-dilutive financing provided

by the French government, notably through the France 2030 investment plan, facilitated

by Bpifrance, as well as by the Grand-Est regional authority and the European Union, within

the scope of several research projects.

"France 2030 is proud to have supported this project since 2020 and to work today with

SPI on the rapid industrialization and effective deployment of the solution for the benefit

of patients. RDS’ story clearly shows how France 2030 is capable of transitioning a project

from the lab stage to becoming an international champion," said Bruno Bonnell, Secretary

General for Investment, in charge of France 2030.

In parallel with this funding round, Laurent Monnin, senior investment director at Bpifrance, joins the company’s strategic board, as does Nicolas Foessel, representing Critical Path Ventures.

“We are delighted to be supporting RDS in this critical phase of its development,” said

Magali Joëssel, director of the SPI fund at Bpifrance. “This funding gives the company the

means to become a leading player in post-operative remote monitoring through

MultiSense, and a pioneer in the medicine of the future. By scaling the manufacturing of

its solution, RDS fully embodies the principle of the SPI fund: funding the industrialization

of innovative technologies that will bring growth and jobs to France.”

“We believe that the key to transforming the healthcare system is useful innovation and

industrial ambition,” said Nicolas Foessel of Critical Path Ventures. “With our investment in

RDS, we are backing a team that combines technological excellence with clinical impact

and a long-term vision for medicine, with emphasis on a more preventive, smoother and

human approach. MultiSense exemplifies this positioning, enabling continuous monitoring

and meeting patients’ particular needs away from the hospital setting.”

“The funding provided by SPI and Critical Path Ventures is a real asset for RDS, which will

be able to ramp-up activities after a launch phase to which MACSF and Capital Grand Est

have contributed,” said Jean-François Rax, partner at Capital Grand Est.

The global market for vital signs monitoring is estimated at USD $15 billion in 2025, and

is expected to grow by an average of 15% each year until 2030. This progression reflects

a strong shift towards home-based patient care both in France and internationally, driven

by the desire to relieve pressure on hospitals, reduce duration of stay and improve postoperative monitoring. The Covid-19 pandemic also brought about a significant shift in

outlook, accelerating the adoption of remote monitoring and strengthening the

requirement for reliable, interoperable digital solutions.

"ERAS (Enhanced Recovery After Surgery) studies have shown the importance of short

hospital stays, even after a major surgery. However, the use of these protocols remains

limited because surgeons have to engage their responsibility. The MultiSense patch offers

an ideal solution: faster patient discharge and a more effective monitoring of vital signs

than in hospital, with considerable medical and economic benefits expected. This is a major

challenge for the sustainability of our healthcare system," concluded Jacques Marescaux,

professor of surgery, president and founder of IRCAD, and member of RDS’ Scientific

Board.

250929 - RDS - fundraising - EN.pdf

Download PDF • 485KB